Lexicon Pharmaceuticals, Inc.
LXRX
Positions held
Your positionsLXRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $783.12M | Enterprise value | $651.75M | Trailing P/E | — | Forward P/E | -9.23 |
| PEG | -13.77 | Price / book | 4.49 | Beta | 1.08 | Dividend yield | 0.00% |
| Revenue growth | -97.6% | Earnings growth | — | Gross margin | 86.0% | Operating margin | -38.4% |
| Profit margin | -147.4% | ROE | -40.2% | ROA | -14.3% | Debt / equity | 0.34 |
| Current ratio | 13.37 | Free cash flow | -$44.77M | Analyst recommendation | buy | Mean target | $4.55 |
| 52w high | $2.68 | 52w low | $1.10 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.7M | $21.1M | $5.5M | $14.2M | $28.9M |
| Op margin | -3835.3% | -4.7% | -269.1% | -85.9% | 12.9% |
| Net income | -$31.8M | -$1.0M | -$15.5M | -$12.8M | $3.3M |
| Gross margin | 94.4% | 99.5% | 96.3% | 99.9% | 99.9% |
| Gross profit | $0.7M | $21.0M | $5.3M | $14.2M | $28.8M |
| Operating income | -$26.5M | -$1.0M | -$14.8M | -$12.2M | $3.7M |
- Revenue -97% vs prior quarter ($0.7M vs $21M).
- Gross margin 94.4% (was 99.5% prior quarter).
- Operating margin compressed to -3835.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $49.8M | $31.1M | $1.2M | $0.1M | — |
| Op margin | -98.2% | -634.2% | -14265.0% | -72489.2% | — |
| Net income | -$50.3M | -$200M | -$177M | -$102M | — |
| Gross margin | 99.4% | 98.0% | 92.9% | 100.0% | — |
| Gross profit | $49.5M | $30.5M | $1.1M | $0.1M | — |
| Operating income | -$48.9M | -$197M | -$172M | -$101M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress
2026-09-28 · Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
2026-09-28 · Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating
2026-09-28 · Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
2026-09-28 · Cantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price Target
2026-09-25 · LX-9211 Market Outlook 2026-2034 | Sales Forecast Highlights Emerging Commercial Opportunities
2026-09-20 · Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
2026-09-01 · Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
2026-08-24 · Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone
2026-08-24 · Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851
Price (daily)
Full chart · RSI · MACD · patterns